Antihypertensive drugs

Carvedilol is a non-selective beta blocker/alpha-1 blocker, used to treat congestive heart failure (CHF) and high blood pressure.An α1- and β-adrenergic receptor antagonist.

CARVEDILOL-D4

Casuarictin.

Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure. Catestatin TFA is a non-competitive nicotinic antagonist acting through

Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure. Catestatin TFA is a non-competitive nicotinic antagonist acting through

Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure. Catestatin TFA is a non-competitive nicotinic antagonist acting through

This enzyme degrades collagen and proteoglycan and can also cause the release of angiotensin II from angiotensin I or angiotensinogen. It has been implicated in connective tissue diseases such as emphysema and rheumatoid arthritis.

Antigen: fusion protein amino acids 1,507-1,733 Isotype: IgG2b Host: mouse, clone S57-46 Cross Reactivity: (+) human, mouse, and rat Cav1.2 Application(s): ICC, IF, IHC, and WB Cav1.

CaV1.3 antagonist-1 is a potent and highly selective Ca V 1.3 L-type calcium channel (LTCC) antagonist with an IC 50 of 1.7 μM. CaV1.3 antagonist-1 inhibits Ca V 1.3 LTCC &gt:600-fold more potently than Ca V 1.2 LTCC. CaV1.3 antagonist-1, a

CaV1.3 antagonist-1 is a potent and highly selective Ca V 1.3 L-type calcium channel (LTCC) antagonist with an IC 50 of 1.7 μM. CaV1.3 antagonist-1 inhibits Ca V 1.3 LTCC &gt:600-fold more potently than Ca V 1.2 LTCC. CaV1.3 antagonist-1, a

CaV1.3 antagonist-1 is a potent and highly selective Ca V 1.3 L-type calcium channel (LTCC) antagonist with an IC 50 of 1.7 μM. CaV1.3 antagonist-1 inhibits Ca V 1.3 LTCC &gt:600-fold more potently than Ca V 1.2 LTCC. CaV1.3 antagonist-1, a

A PPAR&gamma agonist that is 4-fold more potent than rosiglitazone at the PPAR&gamma receptor demonstrating an EC50 value of 0.05 &microM shows high selectivity for PPAR&gamma over PPAR&alpha (EC50 = 3.